logo-loader
viewMycovia Pharmaceuticals

Mycovia Pharmaceuticals developing an oral anti-fungal to treat Recurrent Vulvovalginal Candidiasis

Mycovia Pharmaceuticals CEO Patrick Jordan joined Proactive Investors at the BIO Investor Forum in San Francisco. The privately-held, North Carolina-based company is developing therapies in women’s health, with its lead product candidate, VT-1161, an oral anti-fungal therapy for Recurrent Vulvovalginal Candidiasis (RVVC).

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

NQ Minerals' David Lenigas focused on restructuring debt and upping profits...

NQ Minerals PLC's (LON:NQMI) David Lenigas speaks to Proactive London's Andrew Scott soon after taking over as chairman at the Australia-focused mining group. Production and exploration plans aside, Lenigas also says they're in advanced talks to replace on more favourable terms all the debt...

10 hours, 50 minutes ago

2 min read